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The saga of harmful levodopa (LD) in the treatment of Parkinson’s disease (PD) resulted from outcomes of animal—and
cell culture studies and the clinical observation of motor complication related to the short half life of LD. Further aspects
of LD long term application, the LD associated homocysteine increase and its emerging consequences on progression, and
onset of neuropsychiatric symptoms and of vascular disease are only partially considered. Therapeutic approaches for this
LD-mediated neurotoxic homocysteine increase are vitamin supplementation or LD application with an inhibitor of catechol-
O-methyltransferase (COMT). However, forcing central dopamine metabolism further down the methylation path by central
blocking of COMT and MAO-B may reduce oxidative stress and homocysteine levels. But it may also increase N-methylation of
tetrahydroisoquinolines to neurotoxic N-methylated tetrahydroisoquinolines. These compounds were observed in cerebrospinal
ﬂuid and plasma of long term LD-treated PD patients. Therefore LD application with peripheral COMT inhibition may be safer.
Copyright © 2009 Thomas M¨ uller. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The discussion of the value of levodopa (LD) for treatment
of patients with Parkinson’s disease (PD) focused on a
putative LD toxicity to date. This saga of harmful LD based
on outcomes of animal—and cell culture studies in basic
research and the clinical observation of the manifestation
of long term motor complications. Therefore the Earlier
versus Later L-DOPA (ELLDOPA) trial was designed to
answer whether LD is harmful or not. The outcomes showed
that LD is an eﬃcacious and well-tolerated compound for
treatment of PD patients. This study also provided also
some evidence for progression modifying beneﬁts of LD
in PD patients, since—after a two wash out period of LD
at the end of the trial—the PD patients with prior LD
treatment performed signiﬁcant better than the ones on
placebo. One may assume that LD treatment maintained
body function and prevented onset of secondary long term
changes and adaptation of the body to the manifestation
of PD. This may support the concept of an early diagnosis
of PD with subsequent early initiation of PD treatment.
H o w e v e raf u r t h e rp o s i t i v ee ﬀect of LD may be the growth
hormone inducing and thus putative regenerative eﬀects of
LD [1]. Growth hormone is under debate as an antiageing
compound with multiple eﬃcient regenerative modes of
action in the human body [2]. However the ELLDOPA trial
lasted 9 months; therefore it could not discuss additional
aspects of LD treatment on progression of PD. These points
are related to the inhibition of the main LD metabolising
enzymes, catechol-O-methyltransferase (COMT), and dopa
decarboxylase. Peripheral dopa decarboxylase inhibition
(DDI) supports the predominant conversion of LD to its
metabolite 3-O-methyldopa (3-OMD) by the ubiquitious
enzyme COMT in blood, peripheral tissues and in nigros-
triatal neurons (Figure 1). COMT has a broad detoxiﬁcation
potential in humans [3, 4]. In order to prolong the half life
and thus to increase brain delivery of LD, COMT-inhibitors
were developed as adjuncts to LD/DDI application. Two
compounds are currently available, the only peripherally
acting entacapone and the additional centrally working
tolcapone [5, 6]. COMT inhibition is also under suspicion
to prevent motor complications since the rise and fall of
LD thus striatal dopamine are less intense during COMT
inhibition, that is, entacapone. This supports the concept
of continuous dopaminergic stimulation due to a more
continuous LD brain delivery [7]. But COMT inhibition has2 Cardiovascular Psychiatry and Neurology
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Figure 1: Metabolic pathways of homocysteine generation
and degradation in association with levodopa metabolism.
COMT=catechol-O-methyltransferase,3-OMD=3-O-methyldopa,
CH3=methylgroup.
further beneﬁcial eﬀects on the LD-associated homocysteine
increase [8]. Long-term LD intake promotes homocysteine
elevation, which has an atherosclerosis promoting eﬀect.
An occurrence of increased hazard ratios for both ischemic
heart and cerebrovascular disease is known in LD/DDI-
treated PD patients, who were predominantly treated with
LD monotherapy during the LD era [9, 10]. The conversion
of LD to 3-OMD via the COMT requires Mg2+ as cofactor
and S-adenosylmethionine as methyl donor [11]. Thus O-
methylation of LD to 3-OMD is associated with conversion
of S-adenosylmethionine to S-adenosylhomocysteine and
subsequently homocysteine. Elevated homocysteine levels
appeared in treated PD patients compared to matched
controls [12, 13]. Treated but not previously untreated PD
patients showed augmented homocysteine plasma concen-
trations [14, 15]. The relationship between homocysteine
and 3-OMD plasma levels provided further evidence for an
impact of LD on homocysteine [16].
2. HomocysteineandArteriosclerosis
Both prospective and case-control studies have shown that
an elevated plasma total homocysteine level is an inde-
pendent risk factor for occlusive vascular disease. Various
mechanisms have been suggested for the vascular lesions
associated with hyperhomocysteinemia. The redox property
of the sulfhydryl group of homocysteine, leading to the
formation of reactive oxygen species, is believed to play
a pivotal role. This supports substantial impairment of
endothelial functionandsubsequentatherosclerosis[17,18].
Tie consequence is a vicious circle, since arteriosclerotic
disease of striatal cerebral vessels hypothetically results in
subsequent onset of increased susceptibility to impaired
mitochondrialenergymetabolism,oxidativestress,andbasal
ganglia circuit dysfunction, all of which represent typical,
pathophysiologic features of PD [19].
3. CysteineandArteriosclerosis
Homocysteine is removed either by methylation to methio-
nine or by its irreversible conversion to cysteine (Figure 1).
This is a transsulfuration process [20, 21]. The homocysteine
derivative, cysteine, is a sulfhydryl-containing amino acid
with structural and chemical properties similar to those of
homocysteine. Oxidation of cysteine in vitro also promotes
several processes considered to be involved in atherogenesis
and thrombogenesis. Cysteine has a cytotoxic eﬀect in
vitro against several cell types [20]. Cysteine forms an
adduct with nitric oxide and may thereby impair endothelial
function. Nitric oxide is believed to play a crucial role
in the pathogenesis of chronic neurodegenerative processes
[20]. High levels of homocysteine cause complex changes in
cysteine levels and the overall aminothiol status in plasma
[22]. A number of trials showed a close relationship between
homocysteine and cysteine metabolism in various disease
entities [20]. In plasma, the cysteine concentration is 20-
fold higher than the homocysteine level. Rare information
is available on cysteine levels in PD patients. Previous trials
reported no relevant alterations of cysteine concentrations
in PD patients, but moment of blood sampling in relation
to intake of LD was not deﬁned in detail in that studies
[23–26]. A more recent study deﬁned the moment of blood
sampling one hour after LD/DCI intake and divided the
cohort of PD patients according to their homocysteine level
at the treshold of 15µmol/L [27]. Only PD patients with an
elevation of plasmatic homocysteine above 15 also showed
an increase of cysteine plasma levels. This could have been
due to the signiﬁcant higher dosing of daily LD/DCI and
thesigniﬁcanthighermorningLD/DCIintakeofPDpatients
with a homocysteine concentration above 15 in comparison
with the remaining PD patients and the controls. The found
signiﬁcant correlations between morning LD/DCI dosages
and cysteine, respectively, homocysteine concentrations,
supported this view. Higher LD/DCI intake even seemed
to inﬂuence cysteinyl-glycine levels due to the signiﬁcant
correlations in patients with elevated homocysteine concen-
trations [27].
4. Cysteinyl-GlycineandArteriosclerosis
Metabolically interrelated to homocysteine and cysteine is
cysteinyl-glycine. In plasma, this thiol species also deter-
mines the redox milieu and free radical generation rates.
In another neurodegenerative disorder, Alzheimer’s disease,
cysteinyl-glycine was reduced in plasma. Cysteinyl-glycine is
a metabolite of glutathione. Glutathione depletion plays a
crucial role in chronic neurodegeneration, since this leads to
the accumulation of reactive oxygen species and, ultimately,
oxidative stress related, apoptotic cell death, both of which
are looked upon as essential pathophysiologic features of PD
[22, 28]. All these thiol species—homocysteine, cysteine, and
cysteinyl-glycine—exist in plasma in reduced, oxidized, and
protein-bound forms, interacting with each other through
redox and disulﬁde exchange reactions. Thus, hyperhomo-
cysteinemia should not be considered as an isolated factor in
relation to vascular disease and chronic neurodegeneration.
The associated changes in other plasma aminothiols may
modulate or even mediate atherogenesis, thrombogenesis,
and the neurodegenerative process [20].Cardiovascular Psychiatry and Neurology 3
5.LD-AssociatedHomocysteineIncreaseand
ClinicalConsequences
Homocysteine increase may predispose for neuronal dys-
function and brain atrophy [29, 30]. This toxic impact of
homocysteine on neuronal cell death was shown in sural
nerves of PD patients and in animal trials [19, 31]. Thus,
long-term LD administration may be indirect toxic to neu-
ronal function due to homocysteine elevation [19, 26, 32].
Increase of vascular disease-related thickening of the intima
mediacomplexandanelevatedriskforonsetofneuropsychi-
atric complications, like depression or deteriorated cognitive
function, were also described in association with augmented
homocysteine levels in LD/DDI-treated PD patients [33–
36]. However the outcomes of more recent trials were only
partial conﬁrmatory [37, 38]. This could have been due to a
relative low number of participants, design, and duration of
these studies. Moreover variations of the distribution of the
polymorphism of the Methylenetetrahydrofolate reductase
(MTHFR) gene could have diﬀered between the various
investigated cohorts. In particular the homozygote MTHFR
T/T allele promotes elevated homocysteine levels [33, 39,
40]. Further causes for the controversial outcomes could
result from variations of plasma bioavailability of LD. This
depends on the gastrointestinal absorption and transport
via the gastrointestinal amino acid transporter system. Both
of them are inﬂuenced by gastric emptying time, which,
if reduced, could decrease plasma appearance of LD [41].
Absorption of LD improves with progression of PD and
chronic LD intake. As a result, this may support the risk
of a LD/DDI-associated homocysteine increase [42, 43]. A
further inﬂuence on LD metabolism may result from body
weight. It is known that low body weight is associated
with higher plasma LD levels [44]. All these components,
related with LD metabolism, could also have inﬂuenced
outcomes of trials on the clinical long-term consequences of
the LD/DDI-induced homocysteine increase in PD patients.
Homocysteine levels were mostly determined one time only
inthoseinvestigations. Amorerecentstudydescribesplasma
metabolism of LD as essentially contributing component for
homocysteine elevation after one time LD/DDI administra-
tion [45].
6. HomocysteineIncreaseand LDDegradation
LD metabolism is mainly inﬂuenced by the enzyme activities
of dopadecarboxylase and COMT; the eﬃcacy of inhibitors
of these enzymes might also impact homocysteine levels. In
this respect, application of LD only with a DDI supports
homocysteine elevation, whereas LD administration with
inhibitors of the both LD metabolizing enzymes may reduce
the risk of homocysteine elevation [39, 46]. Experimental
animal studies with a one single LD dose acute treatment
paradigm also showed an impact on homocysteine gen-
e r a t i o ne v e na f t e r1 2 0m i n u t e s[ 47–49]. Combination of
COMT-inhibitorswithLD/DDIalsodecreaseshomocysteine
generation as shown with tolcapone [46]. In rats, this was
also demonstrated with the COMT inhibitor entacapone,
but this is under debate [47]. Observational European
nonprospective investigations reported lower homocysteine
levels in entacapone-treated patients [50–52]. A prospective
clinical study on the eﬀect of entacapone application on
homocysteine levels was negative in PD patients. This trial
might have been under powered because of the folic acid
supplementationintheAmericanandCanadiandiet,leading
to a milder homocysteine increase than expected [53, 54].
Currently these two COMT inhibitors are available, but their
modes of action essentially diﬀer. Tolcapone also acts in the
brain, whereas entacapone only operates in the periphery
[5, 6, 55]. This pharmacological diﬀerence between both
compounds warrants a more general discussion; whether
peripheral or additional central COMT-inhibition is more
suitable to modulate homocysteine synthesis in the long
term. Experimental investigations in cell culture models
showed that COMT activation caused a sustained homo-
cysteine generation in astrocytes and transport to neurons
[26, 56]. Central COMT inhibition may even reduce homo-
cysteine levels in glial and neuronal cells and therefore neu-
rotoxic eﬀects of homocysteine. But exclusive central COMT
inhibition may also support central dopamine metabolism
via monoaminooxidase (MAO), which generates neuronal
oxidative stress [57]. Consequently, one may suggest to
perform central COMT inhibition only with central MAO-
B blocking to reduce free radical synthesis [3]. However
this combination may support glial dopamine metabolism
via MAO-A and reduce the glial oxidation capacity of N-
methylated tetrahydroisoquinolines (TIQ) to their neuronal
neurotoxic cations [58]. But central COMT inhibition may
also decrease O-methylation of endogenous TIQ to 1-
Methyl-TIQ with their neuronal free radical synthesis reduc-
ing properties [58]. Therefore this shift from O-methylation
to N-methylation as a consequence of central COMT
inhibitionmayfurtherenhancesynthesisN-methylatedTIQ,
which induces PD [58, 59].
7.LDAssociated-HomocysteineIncreaseand
VitamineSupplementation
Vitmine B complex and folic acid reduce homocys-
teine, since in example , folic acid catalyses metabolism
of homocysteine to methionine [60]. Folic acid intake,
which promotes the cobalamin dependent degradation of
homocysteine to methionine, or supplementation of B6,
which supports irreversible metabolism of homocysteine
to cysteine, may help [21, 40]. But one animal study
showed that folic acid coadministration did not prevent LD-
associated hyperhomocysteinemia [48].
8. Conclusion andHypothesis
LD is best available compound for PD treatment. Its delivery
to the brain should be more continuous to avoid onset of
motor complications.Long term LD application increases
homocysteine levels in PD patients. This may contribute
to onset of psychiatric side eﬀects, neuronal degeneration,
and vascular disease in PD patients. Treatment options4 Cardiovascular Psychiatry and Neurology
for the LD-mediated homocysteine toxicity are vitamin
supplementation, that is, folic acid and LD application with
COMT inhibition. The possible increased risk for synthesis
of free radicals and N-methylated TIQ in association with
central COMT inhibition may suggest peripheral COMT
inhibition as safer adjunct for LD/DDI therapy
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